These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30810402)

  • 21. [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].
    Knuf M; Neiss A; Wutzler P
    Klin Padiatr; 2006; 218(4):203-12. PubMed ID: 16819701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012.
    Tafuri S; Fortunato F; Cappelli MG; Cozza V; Bechini A; Bonanni P; Martinelli D; Prato R
    Hum Vaccin Immunother; 2015; 11(1):214-9. PubMed ID: 25483538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burden of varicella in the Asia-Pacific region: a systematic literature review.
    Goh AEN; Choi EH; Chokephaibulkit K; Choudhury J; Kuter B; Lee PI; Marshall H; Kim JO; Wolfson LJ
    Expert Rev Vaccines; 2019 May; 18(5):475-493. PubMed ID: 30869552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the role of exogenous boosting in modeling varicella vaccination.
    Talbird SE; La EM; Mauskopf J; Altland A; Daniels V; Wolfson LJ
    Expert Rev Vaccines; 2018 Nov; 17(11):1021-1035. PubMed ID: 30354696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
    Jean-Jasmin LM; Lynette SP; Stefan M; Kai CS; Chew FT; Wah LB
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.
    Wutzler P; Neiss A; Banz K; Goertz A; Bisanz H
    Med Microbiol Immunol; 2002 Oct; 191(2):89-96. PubMed ID: 12410347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cervical cancer screening practices in central and eastern Europe in 2012.
    Maver PJ; Seme K; Korać T; Dimitrov G; Döbrőssy L; Engele L; Iljazović E; Kesić V; Kostova P; Laušević D; Maurina A; Nicula FA; Panayotova Y; Primic Žakelj M; Repše Fokter A; Romejko-Wolniewicz E; Smailytė G; Şuteu O; Świderska-Kiec J; Tachezy R; Valerianova Z; Veerus P; Vīberga I; Znaor A; Zubor P; Poljak M
    Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(1):7-19. PubMed ID: 23674180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Europe ready to embrace a policy of universal varicella vaccination?
    Ramet J; Weil-Olivier C; Sedlak W;
    Int J Clin Pract; 2005 Nov; 59(11):1326-33. PubMed ID: 16236088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Varicella vaccination in Europe: are we ready for a universal childhood programme?
    Sengupta N; Booy R; Schmitt HJ; Peltola H; Van-Damme P; Schumacher RF; Campins M; Rodrigo C; Heikkinen T; Seward J; Jumaan A; Finn A; Olcén P; Thiry N; Weil-Olivier C; Breuer J
    Eur J Pediatr; 2008 Jan; 167(1):47-55. PubMed ID: 17334784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antecedents of use of e-health services in Central Eastern Europe: a qualitative comparative analysis.
    Ćwiklicki M; Schiavone F; Klich J; Pilch K
    BMC Health Serv Res; 2020 Mar; 20(1):171. PubMed ID: 32131820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.
    Holl K; Sauboin C; Amodio E; Bonanni P; Gabutti G
    BMC Public Health; 2016 Oct; 16(1):1103. PubMed ID: 27769206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia.
    Paternina-Caicedo A; De la Hoz-Restrepo F; Gamboa-Garay O; Castañeda-Orjuela C; Velandia-González M; Alvis-Guzmán N
    Vaccine; 2013 Jan; 31(2):402-9. PubMed ID: 23174195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Varicella vaccination in Australia and New Zealand.
    Macartney KK; Burgess MA
    J Infect Dis; 2008 Mar; 197 Suppl 2():S191-5. PubMed ID: 18419396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.
    Bonanni P; Boccalini S; Bechini A; Banz K
    Vaccine; 2008 Oct; 26(44):5619-26. PubMed ID: 18723062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical and economic burden of influenza in the elderly population in central and eastern European countries.
    Kovács G; Kaló Z; Jahnz-Rozyk K; Kyncl J; Csohan A; Pistol A; Leleka M; Kipshakbaev R; Durand L; Macabeo B
    Hum Vaccin Immunother; 2014; 10(2):428-40. PubMed ID: 24165394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data.
    Bollaerts K; Riera-Montes M; Heininger U; Hens N; Souverain A; Verstraeten T; Hartwig S
    Epidemiol Infect; 2017 Oct; 145(13):2666-2677. PubMed ID: 28826422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herpes zoster in the context of varicella vaccination - An equation with several variables.
    Wutzler P; Casabona G; Cnops J; Akpo EIH; Safadi MAP
    Vaccine; 2018 Nov; 36(46):7072-7082. PubMed ID: 30309745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of universal varicella vaccination on the clinical burden of varicella in Colombia: A National database Analysis, 2008-2019.
    Pawaskar M; Gil-Rojas Y; Irene Parellada C; Rey-Velasco A; Beltrán C; Prieto E; Lasalvia P
    Vaccine; 2022 Aug; 40(35):5095-5102. PubMed ID: 35871869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs.
    Sabale U; Karamousouli E; Popovic L; Krasznai ZT; Harrop D; Meiwald A; Hughes R; Weston G; Bencina G
    J Med Econ; 2024 Apr; 27(sup2):1-8. PubMed ID: 38638098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.